FDA Receives Paragraph IV Notice Letter for KUVAN(R)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets

SAN RAFAEL, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug Administration (FDA) in connection with an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of KUVAN ® (sapropterin dihydrochloride) Tablets, although it has not yet received notice of the certification.

BioMarin has 8 patents listed in the FDA Orange Book with expiration dates between 2024 and 2026. BioMarin will evaluate the Paragraph IV certification when it receives the Notice Letter and intends to vigorously enforce its intellectual property rights. By statute, if BioMarin initiates a patent infringement lawsuit against the party submitting the letter within 45 days of receiving the notice letter, then the FDA would be automatically precluded from approving the ANDA for 30 months, or until a district court decision finding the patents invalid or not infringed, whichever occurs earlier. Once the lawsuit is filed, the 30 month stay period will begin as of the date BioMarin was notified of the filing.

"We believe that our patents related to KUVAN are valid and enforceable and intend to assert our rights vigorously." said Jean-Jacques Bienaimé, BioMarin's CEO. "We have thoroughly prepared for this possibility and intend to file suit within the necessary time frame."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include: Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme ® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN ® (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; Firdapse ® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS); and VIMIZIM ® (elosulfase alfa) for the treatment of Morquio A (MPS IVA). Product candidates include: BMN 165 (PEGylated recombinant phenylalanine ammonia lyase), also referred to as PEG PAL, which is currently in Phase 3 clinical development for the treatment of PKU; talazoparib (BMN 673), a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer; BMN 701, a novel fusion of acid alpha glucosidase (GAA) with a peptide derived from insulin like growth factor 2, which is currently in Phase 3 clinical development for the treatment of Pompe disease; BMN 111, a modified C-natriuretic peptide, which is currently in Phase 2 clinical development for the treatment of achondroplasia; and BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1), which is currently in Phase 1 for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease.

For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin ®, VIMIZIM ® , Naglazyme ® , KUVAN ® , Firdapse ® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme ® is a registered trademark of BioMarin/Genzyme LLC.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, implied statements regarding the enforcement of our intellectual property rights. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. These risks and uncertainties include, among others, our ability to successfully enforce our intellectual property rights, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2013 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 85

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 47

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 134

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 122

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 57

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 115

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 102

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading

Top 5 Most Recently Viewed Articles

Mining Stocks: Resilience Amid Market Fluctuations and Trends

Updated Category News Views 466

Understanding the Mining Stocks' Performance In recent discussions, subscribers to the Mining Stock Journal have raised an intriguing question: Will a significant decline in the broader market be necessary for mining stocks to continue their upward trajectory? This line of thought seems to resonate with several market analysts, but it warrants a closer look. Mining stocks...

Continue Reading
Goliath Resources Unveils Ambitious 40,000-Meter Drill Campaign

Updated Category News Views 191

Exciting Times for Goliath Resources Goliath Resources is embarking on a groundbreaking journey with its largest drill campaign yet, focusing entirely on the high-grade gold discovery known as Surebet. This campaign aims to cover an impressive 40,000 meters and will utilize nine drilling rigs. The motivation for such an extensive drilling program stems from the...

Continue Reading
Who Will Dominate the Semiconductor Sector in 2024?

Updated Category News Views 137

The Competitive Landscape of Semiconductors The semiconductor industry is currently experiencing fierce competition, with three key players at the forefront: Broadcom Inc (NASDAQ: AVGO), Micron Technology Inc (NASDAQ: MU), and Marvell Technology Inc (NASDAQ: MRVL). By examining the specific strengths and hurdles each company faces, investors can gain valuable insights...

Continue Reading
Goldman Sachs' Recent Options Activity Shows Enthusiasm

Updated Category News Views 228

The Bullish Sentiment Surrounding Goldman Sachs In recent times, major financial players have shown a notable bullish sentiment towards Goldman Sachs Gr (NASDAQ: GS). Our analysis of the options market reveals intriguing insights through 37 distinctive trades surrounding this financial powerhouse. When we look deeper into the trading data, it's noteworthy that...

Continue Reading
Eramet's Strategies for Enhanced Operational Efficiency in 2025

Updated Category News Views 305

Analyzing Eramet's Strategic Direction in 2025 Eramet's commitment to operational efficiency has never been more critical than in 2025, especially after encountering significant pressures during the first half of the year. The company's recent announcements underscore an enhancement in various operational protocols, demonstrating a resilient approach towards addressing...

Continue Reading